rs7927997 — EMSY EMSY/C11orf30 Atopy Regulatory Variant

Regulatory variant near C11orf30 (EMSY) on chromosome 11q13.5; the T allele reduces EMSY transcriptional repressor activity, releasing TSLP and CCL5 expression in epithelial cells and increasing susceptibility to eosinophilic inflammation, atopic dermatitis, eosinophilic esophagitis, asthma, poly-sensitization, and Crohn's disease

See your personal result for EMSY

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

EMSY and the Epigenetic Gateway to Atopic Disease

The C11orf30 gene — commonly known by its protein product name EMSY — sits at one of the most replicated and broadly acting loci in allergy genetics. Variants at this chromosome 11q13.5 locus have been found to influence risk for atopic dermatitis, asthma, hay fever, food allergy, poly-sensitization to multiple allergens, eosinophilic esophagitis, and inflammatory bowel disease. The rs7927997 variant is an expression quantitative trait locus (eQTL) that modulates EMSY transcript levels in both blood and intestinal tissue, making it a master regulator variant whose effects ripple across the entire atopic spectrum.

The Mechanism

EMSY is a transcriptional repressor11 transcriptional repressor
EMSY silences gene expression by recruiting chromatin-remodeling complexes, including HP1-beta and histone methyltransferase components, to interferon-stimulated gene promoters. Its most important targets in the context of allergy are TSLP (thymic stromal lymphopoietin), a cytokine that acts as the master switch for type-2 allergic inflammation, and CCL5 (RANTES), a chemokine that recruits eosinophils, mast cells, and T helper-2 cells to sites of inflammation.

When EMSY is functioning normally at high levels, it keeps TSLP and CCL5 transcription suppressed in epithelial cells of the skin, esophagus, and gut. The rs7927997 T allele reduces EMSY expression in blood and intestinal tissue — and likely in epithelial barriers more broadly — releasing this brake. The result is elevated TSLP and CCL5 at mucosal surfaces22 elevated TSLP and CCL5 at mucosal surfaces
Fahey et al. 2018 Pediatric Allergy and Immunology (PMID 29663593) showed that EMSY overexpression in eosinophilic esophagitis tissue directly activates TSLP and CCL5 production, linking reduced EMSY repressor activity to eosinophil recruitment and mucosal inflammation, a state that primes dendritic cells and innate lymphoid cells (ILC2s) to initiate and sustain type-2 immune responses.

The rs7927997 T allele is intergenic, sitting in a regulatory region between C11orf30 and LRRC32 (which encodes GARP, a cell-surface docking molecule for TGF-β on regulatory T cells and platelets). Two independent functional signals have been identified at this locus: one regulating EMSY and one regulating LRRC32 expression, suggesting the region operates as a multi-gene regulatory hub for immune and barrier homeostasis.

The Evidence

The first genome-wide significant association at this locus for atopic disease came from a 2009 GWAS of atopic dermatitis33 2009 GWAS of atopic dermatitis
Esparza-Gordillo et al. Nature Genetics 2009; chromosome 11q13.5 rs7927894 (in high LD with rs7927997), OR 1.45, p=7.6×10⁻¹⁰ for eczema in European cohorts, identifying the C11orf30 region as the first reproducible non-FLG genetic risk factor for eczema. Approximately 13% of individuals of European descent are homozygous for the risk allele at this locus, carrying 1.45–1.47-fold elevated atopic dermatitis risk.

rs7927997 itself was identified in a landmark Crohn's disease GWAS meta-analysis of 6,333 cases and 15,056 controls44 Crohn's disease GWAS meta-analysis of 6,333 cases and 15,056 controls
Franke et al. Nature Genetics 2010 — increased Crohn's disease susceptibility loci to 71; rs7927997 T allele OR 1.17, p=5.62×10⁻¹³, consistent with the growing recognition that EMSY variants influence both allergic and autoimmune-inflammatory gut disease through shared immune-regulatory pathways.

The eQTL function of rs7927997 was directly demonstrated by Di Narzo et al. 201655 Di Narzo et al. 2016
Blood and Intestine eQTLs from an Anti-TNF-Resistant Crohn's Disease Cohort; GWAS P = 6.0×10⁻¹³ for the rs7927997-C11orf30 eQTL signal in both blood and intestine, confirming that the T allele reduces EMSY transcript levels in disease-relevant tissues. Because EMSY is a transcriptional repressor of interferon-stimulated gene programs, this downregulation amplifies inflammatory gene expression in both gut and immune cells.

For the allergy side, a multi-centre European study Anto et al. 201566 Anto et al. 2015
C11orf30-rs2155219 (in LD with rs7927997) doubles risk of poly-sensitization; OR = 2.27 by skin prick test to 4+ allergens, p<0.05 demonstrated that the C11orf30 locus specifically amplifies sensitization breadth — the likelihood of reacting to multiple allergens simultaneously — rather than raising risk for any single allergy in isolation. This makes rs7927997 particularly relevant for individuals with multi-allergen profiles.

Practical Actions

Carriers of the T allele have a mildly elevated atopic burden at this locus, manifesting most noticeably as a tendency toward poly-sensitization, elevated IgE, and eosinophilic inflammation at mucosal surfaces (skin, gut, esophagus, airways). The actionable implications focus on: (1) monitoring eosinophil-related biomarkers if relevant symptoms are present, (2) optimizing epithelial barrier nutrition that supports TSLP suppression, and (3) considering anti-type-2 therapies if disease burden is clinically significant.

Interactions

rs7125552 (C11orf30/EMSY haplotype partner): The effect of the rs7927894 risk allele on atopic dermatitis is haplotype-dependent — rs7927894 T effect is significantly larger in individuals who also carry G at rs7125552 (a nearby haplotype partner). Since rs7927997, rs7927894, and rs7125552 all tag the same 11q13.5 regulatory block, compound carriership of risk haplotypes at this region produces additive atopic risk.

rs10751659 (PRG3): PRG3 encodes a paralog of eosinophil major basic protein (MBP) at the same allergy-expansion batch. Eosinophil infiltration at mucosal surfaces — driven in part by the TSLP/CCL5 axis regulated by EMSY — is the primary cytotoxic mechanism these granule proteins execute. Concurrent risk alleles at PRG3 and EMSY represent upstream (recruitment signal) and downstream (effector protein) components of the same eosinophilic damage pathway.

rs2476601 (PTPN22): PTPN22 encodes a phosphatase that brakes T-cell and B-cell activation; its R620W risk allele reduces regulatory T-cell braking. EMSY loss of function (T allele) and PTPN22 R620W loss of T-cell regulation represent parallel mechanisms that simultaneously amplify the type-2 immune response, potentially compounding atopic disease severity.

Genotype Interpretations

What each possible genotype means for this variant.

CC Common Genotype Normal

Full EMSY expression — baseline atopic risk at this chromosome 11q13.5 locus

You carry two copies of the C allele at rs7927997. This is the most common genotype, found in approximately 44% of people globally and slightly more prevalent in East Asian populations. At this locus you carry no copies of the T allele that is associated with reduced EMSY/C11orf30 transcriptional repressor activity and elevated susceptibility to poly-sensitization, atopic dermatitis, eosinophilic esophagitis, and inflammatory bowel disease.

EMSY functions normally in your epithelial and immune cells at this locus, maintaining its repression of TSLP and CCL5 expression. This does not eliminate all atopic risk — genetic influences on allergy and atopy are highly polygenic — but it means you do not carry additional inflammatory burden from this particular regulatory variant.

CT Heterozygous Intermediate

One T allele — modestly elevated atopic susceptibility via reduced EMSY repressor activity

The C11orf30/EMSY locus is one of the most replicated allergy genetics findings: independently associated with eczema, asthma, hay fever, food allergy, eosinophilic esophagitis, and inflammatory bowel disease in GWAS spanning multiple ancestries. The T allele reduces EMSY expression and releases transcriptional repression of TSLP — the master switch cytokine that activates dendritic cells, ILC2s, and ultimately the entire Th2 cascade. rs7927997 T allele carriers show ~37% T allele frequency in Europeans, making it a common risk variant, not a rare one.

The eQTL evidence (Di Narzo et al. 2016, PMID 27336838) is mechanistically precise: rs7927997 directly governs C11orf30 expression in both blood and intestine, with a p-value of 6.0×10⁻¹³, placing it among the most functionally validated regulatory variants in allergy genetics.

TT Homozygous Risk High Risk

Two T alleles — greatest reduction of EMSY repressor activity and highest atopic susceptibility at this locus

TT homozygotes at this C11orf30 locus carry additive risk relative to CT heterozygotes under the dose-response model established by Franke et al. 2010 (PMID 21102463) for Crohn's disease (OR 1.17 per allele → OR ~1.37 for TT vs CC) and by atopic dermatitis GWAS where the 11q13.5 locus reached OR 1.45-1.47 for homozygous risk carriers (Esparza-Gordillo et al. 2009, PMID 19197346).

The mechanistic link is precise: the T allele is an eQTL that reduces EMSY expression in blood and intestinal tissue (Di Narzo et al. 2016, PMID 27336838, p=6.0×10⁻¹³). EMSY represses TSLP and CCL5 transcription at mucosal surfaces. Less EMSY expression means more TSLP → more ILC2 and Th2 activation → more eosinophil recruitment via CCL5 and IL-5 → higher eosinophil load at skin, esophageal, gut, and airway mucosa.

The poly-sensitization phenotype is particularly noteworthy: the C11orf30 locus doubles the risk of reacting to four or more allergens simultaneously (OR 2.27 by skin prick test, Anto et al. 2015, PMID 25546184). This is distinct from having a single allergy — it is a systemic atopic bias toward multi-allergen responsiveness that emerges specifically from reduced EMSY epigenetic control.

Concurrently, the same reduced EMSY activity in intestinal tissue disrupts the interferon-pathway transcriptional repression needed for barrier homeostasis, explaining the overlap with Crohn's disease susceptibility at this locus — allergy and IBD risk share this epigenetic axis.